Growing Pains
There is no one-size-fits-all model for pharma companies seeking input from patients. There was no blueprint when companies took their first tentative steps a few years ago and there is none now as they enter the next era – scaling up patient-centric efforts to become business as usual.“When I talk to patient organizations, many times they ask, Why does wanting better patient outcomes require a culture shift in pharma?” says Laura McKeaveney, Head of Global Patient Advocacy at Novartis. “But that’s not what requires the culture shift.”People who work in pharma want better patient outcome...
Source: EyeForPharma - December 12, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Thousands more women affected by Capita cervical screen blunder
Time to strip the company of its NHS contract, urge doctors ’ leaders Related items fromOnMedica The risk factors for cervical cancer Home samples for cervical screening tests could boost uptake Cervical smear blunder affects thousands New test could mean cervical cancer screening could stop sooner Vaccine could 'eradicate' cervical cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 12, 2018 Category: UK Health Source Type: news

National lung disease plan needed to help ease winter pressures, experts urge
These illnesses account for nearly one million A&E attendances, with admissions peaking sharply in winter, says British Thoracic Society Related items fromOnMedica Adjuvanted trivalent flu vaccine best option for over-65s UK ‘can and should do better’ in many areas of healthcare UK falls behind other nations in preventing avoidable death Cancer strategies failed to improve one-year survival Lung experts call for ‘national plan for lung cancer’ (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 11, 2018 Category: UK Health Source Type: news

Medical advances could soon spare patients surgery, say experts
Better drugs, vaccination and genomics will help to make some operations obsoleteThousands of people every year could be spared surgery for cancer and worn-out joints thanks to better drugs, vaccination and advances in genomics, a report by medical experts predicts.Developments in surgery could also make many operations less invasive and more effective, while more patients would have preventive procedures to stop an illness worsening.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 7, 2018 Category: Science Authors: Denis Campbell Health policy editor Tags: Medical research Health policy Human Genome Project Society Science UK news Biology Genetics Doctors Source Type: news

The Future of HIV Treatment Might Not Involve Pills
HIV treatments have come a long way in the more than 30 years since the virus was first identified. Powerful antiretroviral drugs (ARVs) can now keep the virus controlled at levels that current tests cannot detect in the blood. Perhaps just as important, people who take these drugs diligently soon after they’re infected are unlikely to pass the virus to others. But the treatment isn’t perfect. Those with HIV need to take a pill every day for the rest of their lives, and even if they do, the virus can easily morph to become resistant to the drugs. That’s why patients on ARV treatment should faithfully moni...
Source: TIME: Health - December 1, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime HIV/AIDS onetime Source Type: news

A cancer drug may help treat human papillomavirus infections
(University of Alabama at Birmingham) Preclinical experiments suggest the cancer drugs vorinostat, belinostat and panobinostat might be repurposed to treat infections caused by human papillomaviruses, or HPVs. Highly efficacious vaccines against HPV infection exist -- including the recently approved Gardasil 9, which immunizes against nine genotypes of HPV known to cause cervical, vulvar, vaginal and anal cancers. But the vaccine needs to be given before a person becomes sexually active, since it has no therapeutic efficacy against existing HPV infections. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2018 Category: Cancer & Oncology Source Type: news

U.S. Life Expectancy Dropped for the Third Year in a Row. Drugs and Suicide Are Partly to Blame
U.S. life expectancy dropped in 2017 for the third consecutive year, as deaths by suicide and drug overdose continue to claim more American lives. The average American could expect to live to 78.6 years old in 2017, down from 78.7 in 2016, according to data released Thursday by the Centers for Disease Control and Prevention’s National Center for Health Statistics (NCHS). That decline may be modest, but it marks the third year in a row that life expectancy at birth has fallen — a noteworthy phenomenon, since the previous multiyear drop recorded by the NCHS was in the early 1960s. The modern trend seems to be pr...
Source: TIME: Health - November 29, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime public health Source Type: news

Mutations boost immunity: Toward a cancer vaccine
(Arizona State University) In a new study, Stephen Albert Johnston and his colleagues describe a method for pinpointing tumor-specific factors in blood that can elicit a protective immune response in the body and may one day be harnessed to produce an effective vaccine against the disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 26, 2018 Category: Biology Source Type: news

How fake news is SERIOUSLY damaging our health
From vaccines and heart health to cancer drugs and diet, experts have reported a huge increase in misinformation online, which at best obfuscates the truth and at worst contradicts it entirely. (Source: the Mail online | Health)
Source: the Mail online | Health - November 25, 2018 Category: Consumer Health News Source Type: news

2018 Surge In Measles In Europe And US Show Importance Of Herd Immunity
The measles news continues: an outbreak in New Jersey, continuing outbreaks in Europe, and a mother of a child with cancer pleads with people to get the measles vaccine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 25, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

2018 Surges In Measles In Europe And US Show Importance Of Herd Immunity
The measles news continues: an outbreak in New Jersey, continuing outbreaks in Europe, and a mother of a child with cancer pleads with people to get the measles vaccine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 25, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

2018 Surges In Measles In Europe And U.S. Show Importance Of Herd Immunity
The measles news continues: an outbreak in New Jersey, continuing outbreaks in Europe, and a mother of a child with cancer pleads with people to get the measles vaccine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 25, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Women over 75 should still be invited for mammography
Incidence of breast cancer in this age group is comparatively high, and largely invasive Related items fromOnMedica Breast cancer age profile younger in non-white women Cancer strategies failed to improve one-year survival Social media could help raise breast screening take-up JCVI recommends universal HPV vaccination NICE guidance aims at earlier cancer diagnosis by GPs (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 20, 2018 Category: UK Health Source Type: news

NHS cancer screening programmes set for major review
Review will be part of NHS Long-Term Plan Related items fromOnMedica Experts call for wider HPV vaccination Cancer strategies failed to improve one-year survival Third of emergency cancer presenters never saw GP Young women shun smear tests out of embarrassment Cancer diagnosis via screening offers best outcomes (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 16, 2018 Category: UK Health Source Type: news

Cervical smear blunder affects thousands
More than 40,000 women left in dark over screening error Related items fromOnMedica Is Capita too vital to fail? GP back-office privatisation 'put patients at risk' Capita primary care outsourcing was ‘shambles’ say MPs The HPV vaccine and cervical screening The risk factors for cervical cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 15, 2018 Category: UK Health Source Type: news

Mayo Foundation Journalist Residency: Application Deadline December 11
In this five-day fellowship program sponsored by the Mayo Foundation for Medical Education and Research, journalists will receive a behind-the-scenes, in-depth look at what?s new and what?s next in several medical specialties. Topics will include aging, cancer, brain injuries and diseases, transplant medicine, vaccines and developing technologies such as regenerative medicine, telemedicine and simulation-based medical [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - November 14, 2018 Category: Hospital Management Source Type: news

Medical News Today: New way to manipulate immune cells may treat cancer, autoimmune disease
Altering levels of a molecule that T cells need to grow could help the body fight cancer and lead to new treatments for autoimmune disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2018 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

Biotech unicorn Moderna files for IPO of up to $500M
One of the biotech industry's largest unicorns, Cambridge-based Moderna Therapeutics, is planning to go public with an IPO of as much as $500 million, according to documents filed Friday. Moderna is developing messenger RNA molecules, including cancer vaccines, that executives estimates could impact dozens of diseases. The company currently has 10 drug products in clinical trials and another 11 drugs in preclinical development. The company filed documents with the SEC on Friday t o seek up to… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 9, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Biotech unicorn Moderna files for IPO of up to $500M
One of the biotech industry's largest unicorns, Cambridge-based Moderna Therapeutics, is planning to go public with an IPO of as much as $500 million, according to documents filed Friday. Moderna is developing messenger RNA molecules, including cancer vaccines, that executives estimates could impact dozens of diseases. The company currently has 10 drug products in clinical trials and another 11 drugs in preclinical development. The company filed documents with the SEC on Friday t o seek up to… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 9, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Childhood Cancer Survivors Benefit From HPV Vaccine Childhood Cancer Survivors Benefit From HPV Vaccine
When healthcare providers recommend the HPV vaccine to survivors of childhood cancer, the patients take the advice to heart and are more likely to get vaccinated, according to new research.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2018 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Health Tip: Understanding the HPV Vaccine
-- The HPV vaccine protects against human papillomavirus, which has been shown to cause cancer in males and females, the American Cancer Society says. More than 270 million doses have been administered since 2006, reports the society, saying studies... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 8, 2018 Category: General Medicine Source Type: news

HPV Vaccination Rates Continue to Lag in U.S.
Title: HPV Vaccination Rates Continue to Lag in U.S.Category: Health NewsCreated: 11/6/2018 12:00:00 AMLast Editorial Review: 11/7/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 7, 2018 Category: Cancer & Oncology Source Type: news

HPV Vaccination Rates Continue to Lag in U.S.
(Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - November 7, 2018 Category: Cancer & Oncology Source Type: news

Too Few Americans Get The HPV Vaccine
HPV (human papillomavirus) vaccination has increased in recent years, rates remain well below the government's 2020 goal of 80 percent of age-eligible adolescents, according to a recent report by the President’s Cancer Panel. (Source: WebMD Health)
Source: WebMD Health - November 6, 2018 Category: Consumer Health News Source Type: news

HPV Vaccination Rates Continue to Lag in U.S.
TUESDAY, Nov. 6, 2018 -- HPV vaccination rates are still too low to cut cervical cancer cases as much as is possible in the United States, a new report warns. While HPV (human papillomavirus) vaccination has increased in recent years, rates remain... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 6, 2018 Category: General Medicine Source Type: news

HPV Vaccine Uptake Low Despite Prior Calls to Action HPV Vaccine Uptake Low Despite Prior Calls to Action
More action is needed to increase HPV vaccine uptake in the United States and elsewhere, according to the President's Cancer Report.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 5, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Public awareness of mouth cancer symptoms low, despite sharp rise in cases
Disease accounts for more than 8000 diagnoses and nearly 3000 deaths every year Related items fromOnMedica JCVI recommends universal HPV vaccination One or two doses of HPV jab may be enough Scotland launches its ‘Detect Cancer Early’ campaign Ditch habit for longer survival after head and neck cancer, smokers urged Obesity as cause of cancer set to overtake smoking (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 5, 2018 Category: UK Health Source Type: news

HPV Vaccination Uptake Increasing, but Still Too Low
FRIDAY, Nov. 2, 2018 -- Although progress has been made in increasing human papillomavirus (HPV) vaccination, coverage is still too low to achieve full cancer prevention potential, according to a report from the President's Cancer Panel published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2018 Category: Pharmaceuticals Source Type: news

A culturally tailored intervention increased HPV vaccination of Asian-American adolescents
(American Association for Cancer Research) A culturally tailored multilevel strategy designed to remove barriers to human papillomavirus (HPV) vaccination among low-income, mostly Chinese-American adolescent girls and boys significantly increased vaccine uptake. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 2, 2018 Category: Cancer & Oncology Source Type: news

New test could mean cervical cancer screening could stop sooner
Women with negative HPV DNA test may not need ongoing screening Related items fromOnMedica JCVI recommends universal HPV vaccination Experts call for wider HPV vaccination Some doctors misunderstand smear test says GP Vaccinating girls against HPV benefits men Parents unsure of HPV vaccine for daughters (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 2, 2018 Category: UK Health Source Type: news

Who Should Be Getting the HPV Vaccine Now? Who Should Be Getting the HPV Vaccine Now?
A recent expanded age indication gives PCPs another chance to prevent HPV-related cancer.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2018 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.10/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

Oncologists demand more education on the use of biosimilars: ESMO takes action
(European Society for Medical Oncology) Biological medicines are responsible for some of the most promising innovations in cancer treatment, including immunotherapy, targeted drugs and vaccines -- but they are also expensive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

Scientists develop DNA molecule that may one day be used as 'vaccine' for prostate cancer
(City of Hope) Researchers from City of Hope have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer. Their novel two-step strategy eliminates STAT3 and toll-like receptor 9. The short DNA programmed by City of Hope researchers temporarily lifted the defense shield of tumors and awakened the immune system in human cell and mouse models to eradicate difficult-to-treat prostate cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: news

Immune Design lays off workers and shifts course after halting lead cancer vaccine trial
The layoffs amount to about 20 percent of Immune Design's workforce in Seattle and San Francisco. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 16, 2018 Category: Biotechnology Authors: Casey Coombs Source Type: news

UCLA neurosurgeon named to National Academy of Medicine
Dr. Linda Liau, an internationally renowned neurosurgeon-scientist and chair of the neurosurgery department at theDavid Geffen School of Medicine at UCLA, has been elected by her peers to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.Membership honors people who have demonstrated outstanding professional achievements, commitment to service and contributions to the advancement of the medical sciences, health care and public health.A scientist in UCLA ’sJonsson Comprehensive Cancer Center, Liau has devoted the past 25 years to developing and refining treatment strategi...
Source: UCLA Newsroom: Health Sciences - October 15, 2018 Category: Universities & Medical Training Source Type: news

Cancer vaccine developer restructures after axing lead drug trial
Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 12, 2018 Category: Pharmaceuticals Authors: Casey Coombs Source Type: news

Cancer vaccine developer restructures after axing lead drug trial
Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 12, 2018 Category: Biotechnology Authors: Casey Coombs Source Type: news

Is the next big step in cancer therapy personalized vaccines?
(University of California - San Diego) Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic. Tamara enrolled in a first-of-its-kind, pilot study at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to boost an anti-tumor immune response. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 12, 2018 Category: Biology Source Type: news

Mayo Clinic researchers study immunity-boosting vaccine to target aggressive form of breast cancer
Treating breast cancer has long involved addressing two problems: the elimination of cancer cells from the tumor and potential disease recurrence. The key may be to harness the full capabilities of the body?s immune system to do both jobs. On Mayo Clinic?s Florida campus, a team of researchers has a new anti-cancer vaccine in the [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - October 10, 2018 Category: Hospital Management Source Type: news

HER2-Targeted Cancer Vaccine Shows Promise in Early Trial
A novel cancer vaccine targeting HER2-positive malignancies has progressed quickly from mouse trials into early-phase human trials, with promising results. (Source: CancerNetwork)
Source: CancerNetwork - October 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

HPV Vaccine Approved for People Through Age 45
(Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - October 9, 2018 Category: Cancer & Oncology Source Type: news

WATCH: HPV vaccine approved for men and women ages 27 to 45
Dr. Jennifer Ashton discusses what to know about the HPV vaccine now being approved for an older age group, and who should get the vaccine, which is meant to prevent cervical cancer. (Source: ABC News: Health)
Source: ABC News: Health - October 8, 2018 Category: Consumer Health News Tags: GMA Source Type: news

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old
The U.S. Food and Drug Administration approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine. (Source: World Pharma News)
Source: World Pharma News - October 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA expands use of HPV vaccine to adults 27 to 45
The FDA approved the HPV vaccine Gardasil 9 for use in adults ages 27 to 45 after studies showed it provided protection against genital warts and certain cancers. (Source: CNN.com - Health)
Source: CNN.com - Health - October 6, 2018 Category: Consumer Health News Source Type: news

HPV Vaccine Expanded for People Ages 27 to 45
The Food and Drug Administration has approved the use of Gardasil 9, a vaccine against nine strains of the human papillomavirus for older age groups. (Source: NYT Health)
Source: NYT Health - October 6, 2018 Category: Consumer Health News Authors: DENISE GRADY and JAN HOFFMAN Tags: Human Papillomavirus (HPV) Gardasil (Vaccine) Vaccination and Immunization Sexually Transmitted Diseases Food and Drug Administration Merck & Company Inc Cancer Source Type: news

Adults Up to Age 45 Can Now Get the HPV Vaccine
Adults up to age 45 can now be vaccinated against human papillomavirus (HPV), reducing their chances of getting cervical, oral and other cancers. The Food and Drug Administration (FDA) announced Friday that Gardasil 9, a vaccine that works against nine different types of HPV, is now approved for both men and women between the ages of 27 and 45. Previously, it was approved only for those between the ages of nine and 26, and recommended for all children at age 11 or 12. “Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” Dr. Peter M...
Source: TIME: Health - October 6, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime public health Source Type: news

FDA approves HPV vaccine for people up to 45
Expanded vaccination age could boost efforts against HPV-caused cancers. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 5, 2018 Category: Consumer Health News Authors: Laurie McGinley Source Type: news

FDA expands use of cervical cancer vaccine up to age 45
US regulators expand use of Merck's cervical cancer to women and men up to age 45 (Source: ABC News: Health)
Source: ABC News: Health - October 5, 2018 Category: Consumer Health News Tags: Health Source Type: news